Aadi Bioscience is a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications. Co.'s main product candidate, AKB-9778, a small molecule inhibitor of the Tie2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. AKB-9778 works by inhibiting vascular endothelial protein tyrosine phosphatase, an enzyme that is upregulated in diabetic eye disease and that is responsible for inactivating Tie2. Co. has AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1 alpha). AKB-4924, now called GB004, is being developed for the treatment of inflammatory bowel disease. We show 1 historical shares outstanding datapoints in our coverage of AADI's shares outstanding history.
Understanding the changing numbers of AADI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AADI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AADI by allowing them to research AADI shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
